Lung cancer
Lung cancer can be effectively treated with the following types of immunotherapy treatments.
Targeted antibodies:
- Ramucircumab
Ramucirumab is a monoclonal antibody which aids in targeting the VEGFR2/VEGF pathway by inhibiting the growth of blood vessel tumors. Ramucirumab is a first-line therapy for the patients of non-small cell lung cancer (NSCLC).
- Necitumumab
Necitumumab is a monoclonal antibody which targets the EGFR pathway and patients of advanced non-small cell lung cancer (NSCLC) as a fist-line therapy.
- Bevacizumab
Bevacizumab is a monoclonal antibody which helps in targeting the VEGFR/VEGF pathway. Bevacizumab inhibits the growth of tumor in blood vessels and FDA approves the use of this monoclonal antibody in the case of patients with severe non-small cell lung cancer (NSCLC) as a first mode of therapy.